LIXTE生物技术正在扩大其癌症研究的范围,超越PPP2A,以采用多种药物方法应对重癌症。 LIXTE Biotechnology is broadening its cancer research beyond PP2A to tackle tough cancers with multiple drug approaches.

LIXTE生物技术已经扩大了其肿瘤研究的范围,超越了最初对PP2A酶调节法的重视,现在对癌症治疗采取多模式办法。 LIXTE Biotechnology has expanded its oncology research beyond its initial focus on PP2A enzyme modulation, now pursuing a multi-modal approach to cancer treatment. 该公司正在推动针对各种癌症途径的多种药物候选者,旨在提高治疗效力和解决抗药性问题。 The company is advancing multiple drug candidates targeting various cancer pathways, aiming to enhance therapeutic efficacy and address resistance issues. 这一战略转变反映出为使其输油管多样化和改善难以治疗的癌症患者的治疗结果作出了更广泛的努力。 This strategic shift reflects a broader effort to diversify its pipeline and improve outcomes for patients with difficult-to-treat cancers.